An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma

Mol Cancer. 2021 Apr 6;20(1):63. doi: 10.1186/s12943-021-01357-z.
No abstract available

Keywords: CRISPR/Cas9 screening; EGLN1; HIF1A; KRAS; Lung cancer.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung / drug therapy
  • Adenocarcinoma of Lung / genetics*
  • Adenocarcinoma of Lung / metabolism
  • Adenocarcinoma of Lung / pathology
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor*
  • Disease Management
  • Disease Susceptibility
  • Gene Knockout Techniques
  • Genomics* / methods
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Hypoxia-Inducible Factor-Proline Dioxygenases / genetics*
  • Hypoxia-Inducible Factor-Proline Dioxygenases / metabolism
  • Models, Biological
  • Molecular Targeted Therapy
  • Mutation*
  • Proto-Oncogene Proteins p21(ras) / genetics*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • KRAS protein, human
  • EGLN1 protein, human
  • Hypoxia-Inducible Factor-Proline Dioxygenases
  • Proto-Oncogene Proteins p21(ras)